Drugs /

omburtamab i-124

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunoconjugate consisting of the iodine I 124-radiolabeled murine IgG1 monoclonal antibody (MoAb) 8H9 directed against the cell surface glycoprotein CD276 (4Ig-B7-H3) with potential for radioimaging using positron emission tomography (PET). Through convection enhanced delivery, iodine I 124 monoclonal antibody 8H9 binds to the 4Ig domain of CD276, in turn CD276 expressing tumor cells may be visualized upon PET imaging of the iodine I 124 moiety. CD276, a tumor associated antigen and member of the B7 family of co-stimulatory proteins, suppresses natural killer (NK) cell and cytotoxic T-lymhocyte activation; it is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and its expression is associated with increased aggressiveness, poor prognosis and resistance.

Clinical Trials

View Clinical Trials for omburtamab i-124

Omburtamab i-124 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating omburtamab i-124, 1 is phase 1 (1 open).

Diffuse intrinsic pontine glioma is the most common disease being investigated in omburtamab i-124 clinical trials [2].

Drug Details

Synonyms [2]:
124i-omburtamab, iodine i 124 moab 8h9, iodine i 124 monoclonal antibody 8h9, 124i-8h9, iodine i 124 moab 8h9
Drug Target(s) [2]:
CD276
NCIT ID [1]:
C99632

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.